Top

International Journal of Diabetes in Developing Countries

Published in:

01-03-2013 | Original Article

Associations of apolipoprotein A5 with triglyceride, adiponectin and insulin resistance in patients with impaired glucose regulation and type 2 diabetes mellitus

Authors: Yang Yan, Huacong Deng, Long Jian, Yanxin Su, Yongling Li, Gongpu Mi

Published in: International Journal of Diabetes in Developing Countries | Issue 1/2013

Abstract

Hypertriglyceridemia (HTG) is an important feature of lipid metabolism abnormality in patients with type 2 diabetes mellitus (T2DM). Apolipoprotein A5 (apoA5) is positively correlated with triglycerides (TG) and insulin resistance (IR). However, its relationship with TG in humans is still controversial till now. Further, its exact mechanism in TG reducing also remains unclear. Meanwhile, adiponectin (APN) can also inhibit TG in humans. Whether there is any association between apoA5 and APN in TG inhibition remains to be explored. This study was taken to investigate the relationships among apoA5, TG, APN and IR in patients with impaired glucose regulation (IGR) and T2DM, the levels of apoA5, TG and APN in the plasma were detected in the current study. Thirty five patients with newly-diagnosed T2DM (T2DM group), 30 patients with IGR (IGR group), and 35 sex- and age-matched normal controls (NGT group) were studied. All the subjects underwent an intravenous glucose tolerance test (IVGTT). Fasting apoA5 and APN were detected by an enzyme linked immunosorbent assay (ELISA). Fasting free fatty acid was measured using colorimetry. Homeostasis model assessment of insulin resistance (HOMA-IR) was made. The plasmic apoA5 and APN levels in the T2DM and IGR groups were lower than that in the NGT group. Furthermore, the levels of apoA5 and APN in the T2DM group were lower than those in IGR group (P < 0.05). ApoA5 was negatively correlated with TG, FFA, 2hFFA, LDL-C, FPG, 2hPG, FINS, HOMA-IR, BMI, and WHR, but positively correlated with APN and HDL-C. The multiple linear regression analysis showed TG, APN, FFA, WHR and HOMA-IR were independent factors of apoA5. Down-regulated apoA5 and APN has a synergistic effect in the process from NGT to IGR and then to T2DM. They can increase FFA expression through participating in the occurrence and development of HTG and IR.

Pennacchio LA, Olivier M, Hubacek JA, Cohen JC, Cox DR, Fruchart JC, et al. An apolipoprotein influencing triglycerides in humans and mice revealed by comparative sequencing. Science. 2001;294:169–73.PubMedCrossRef

van der Vliet HN, Sammels MG, Leegwater AC, Levels JH, Reitsma PH, Boers W, et al. Apolipoprotein A-V: a novel apolipoprotein associated with an early phase of liver regeneration. J Biol Chem. 2001;276:44512–20.PubMedCrossRef

Priore OC, Pisciotta L, Li VG, Sambataro MP, Cantafora A, Bellocchio A, et al. Inherited apolipoprotein A-V deficiency in severe hypertriglyceridemia. Arterioscler Thromb Vasc Biol. 2005;25:411–7.

Dallinga-Thie GM, van Tol A, Hattori H, van Vark-van DZL, Jansen H, Sijbrands EJ. Plasma apolipoprotein A5 and triglycerides in type 2 diabetes. Diabetologia. 2006;49:1505–11.PubMedCrossRef

Dorfmeister B, Brandlhofer S, Schaap FG, Hermann M, Fürnsinn C, Hagerty BP, et al. Apolipoprotein AV does not contribute to hypertriglyceridaemia or triglyceride lowering by dietary fish oil and rosiglitazone in obese Zucker rats. Diabetologia. 2006;49:1324–32.PubMedCrossRef

Hahne P, Krempler F, Schaap FG, Soyal SM, Höffinger H, Miller K, et al. Determinants of plasma apolipoprotein A-V and APOA5 gene transcripts in humans. J Intern Med. 2008;264:452–62.PubMedCrossRef

Alborn WE, Prince MJ, Konrad RJ. Relationship of apolipoprotein A5 and apolipoprotein C3 levels to serum triglycerides in patients with type 2 diabetes. Clin Chim Acta. 2007;378:154–8.PubMedCrossRef

Schaap FG, Nierman MC, Berbee JF, Hattori H, Talmud PJ, Vaessen SF, et al. Evidence for a complex relationship between apoA-V and apoC-III in patients with severe hypertriglyceridemia. J Lipid Res. 2006;47:2333–9.PubMedCrossRef

Henneman P, Schaap FG, Havekes LM, Rensen PC, Frants RR, van Tol A, et al. Plasma apoAV levels are markedly elevated in severe hypertriglyceridemia and positively correlated with the APOA5 S19W polymorphism. Atherosclerosis. 2007;193:129–34.PubMedCrossRef

10.

Kashyap S, Belfort R, Gastaldelli A, Pratipanawatr T, Berria R, Pratipanawatr W, et al. A sustained increase in plasma free fatty acids impairs insulin secretion in nondiabetic subjects genetically predisposed to develop type 2 diabetes. Diabetes. 2003;52:2461–74.PubMedCrossRef

11.

Storgaard H, Poulsen P, Ling C, Groop L, Vaag AA. Relationships of plasma adiponectin level and adiponectin receptors 1 and 2 gene expression to insulin sensitivity and glucose and fat metabolism in monozygotic and dizygotic twins. J Clin Endocrinol Metab. 2007;92:2835–9.PubMedCrossRef

12.

Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 1998;15:539–53.PubMedCrossRef

13.

World Health Organization. Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser. 2000;894:1–253.

14.

Wat NM, Lam TH, Janus ED, Lam KS. Central obesity predicts the worsening of glycemia in southern Chinese. Int J Obes Relat Metab Disord. 2001;25:1789–93.PubMedCrossRef

15.

Tan KC, Wat NM, Tam SC, Janus ED, Lam TH, Lam KS. C-reactive protein predicts the deterioration of glycemia in Chinese subjects with impaired glucose tolerance. Diabetes Care. 2003;26:2323–8.PubMedCrossRef

16.

Van Gaal LF, Mertens IL, De Block CE. Mechanisms linking obesity with cardiovascular disease. Nature. 2006;444:875–80.PubMedCrossRef

17.

Siri P, Candela N, Zhang YL, Ko C, Eusufzai S, Ginsberg HN, et al. Post-transcriptional stimulation of the assembly and secretion of triglyceride-rich apolipoprotein B lipoproteins in a mouse with selective deficiency of brown adipose tissue, obesity, and insulin resistance. J Biol Chem. 2001;276:46064–72.PubMedCrossRef

18.

Yu YH, Ginsberg HN. Adipocyte signaling and lipid homeostasis: sequelae of insulin-resistant adipose tissue. Circ Res. 2005;96:1042–52.PubMedCrossRef

19.

Miyashita Y, Shirai K, Itoh Y, Sasaki H, Totsuka M, Murano T, et al. Low lipoprotein lipase mass in preheparin serum of type 2 diabetes mellitus patients and its recovery with insulin therapy. Diabetes Res Clin Pract. 2002;56:181–7.PubMedCrossRef

20.

Vaessen SF, Dallinga-Thie GM, Ross CJ, Splint LJ, Castellani LW, Rensen PC, et al. Plasma apolipoprotein AV levels in mice are positively associated with plasma triglyceride levels. J Lipid Res. 2009;50:880–4.PubMedCrossRef

21.

Huang XS, Zhao SP, Hu M, Bai L, Zhang Q, Zhao W. Decreased apolipoprotein A5 is implicated in insulin resistance-related hypertriglyceridemia in obesity. Atherosclerosis. 2010;210:563–8.PubMedCrossRef

22.

Talmud PJ, Cooper JA, Hattori H, Miller IP, Miller GJ, Humphries SE. The apolipoprotein A-V genotype and plasma apolipoprotein A-V and triglyceride levels: prospective risk of type 2 diabetes results from the Northwick Park Heart Study II. Diabetologia. 2006;49:2337–40.PubMedCrossRef

23.

Henneman P, Schaap FG, Havekes LM, et al. Plasma apoAV levels are markedly elevated in severe hypertriglyceridemia and positively correlated with the APOA5 S19W polymorphism. Atherosclerosis. 2007;193:129–34.PubMedCrossRef

24.

Dallinga-Thie GM, van Tol A, Hattori H, van Vark-van der Zee LC, Jansen H, Sijbrands EJ. Plasma apolipoprotein A5 and triglycerides in type 2 diabetes. Diabetologia. 2006;49:1505–11.PubMedCrossRef

25.

Niculescu LS, Vladica M, Sima AV. Association of APOA5 and APOC3 gene polymorphisms with plasma apolipoprotein A5 level in patients with metabolic syndrome. Biochem Biophys Res Commun. 2010;391:587–91.PubMedCrossRef

26.

Hyun YJ, Jang Y, Chae JS, Kim JY, Paik JK, Kim SY, Yang JY, Ordovas JM, Ko YG, Lee JH. Association of apolipoprotein A5 concentration with serum insulin and triglyceride levels and coronary artery disease in Korean men. Atherosclerosis. 2009;205:568–73.

27.

Chan DC, Watts GF, Nguyen MN, Barrett PH. Apolipoproteins C-III and A-V as predictors of very-low-density lipoprotein triglyceride and apolipoprotein B-100 kinetics. Arterioscler Thromb Vasc Biol. 2006;26:590–6.PubMedCrossRef

28.

Ishihara M, Kujiraoka T, Iwasaki T, Nagano M, Takano M, Ishii J, et al. A sandwich enzyme-linked immunosorbent assay for human plasma apolipoprotein A-V concentration. J Lipid Res. 2005;46:2015–22.PubMedCrossRef

29.

Hirabara SM, Curi R, Maechler P. Saturated fatty acid-induced insulin resistance is associated with mitochondrial dysfunction in skeletal muscle cells. J Cell Physiol. 2010;222:187–94.PubMedCrossRef

30.

Nowak M, Helleboid-Chapman A, Jakel H, Martin G, Duran-Sandoval D, Staels B, et al. Insulin-mediated down-regulation of apolipoprotein A5 gene expression through the phosphatidylinositol 3-kinase pathway: role of upstream stimulatory factor. Mol Cell Biol. 2005;25:1537–48.PubMedCrossRef

Title: Associations of apolipoprotein A5 with triglyceride, adiponectin and insulin resistance in patients with impaired glucose regulation and type 2 diabetes mellitus
Authors: Yang Yan
Huacong Deng
Long Jian
Yanxin Su
Yongling Li
Gongpu Mi
Publication date: 01-03-2013
Publisher: Springer-Verlag
Published in: International Journal of Diabetes in Developing Countries / Issue 1/2013
Print ISSN: 0973-3930
Electronic ISSN: 1998-3832
DOI: https://doi.org/10.1007/s13410-012-0102-2

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2013

New estimates of pre-diabetes and type 2 diabetes prevalence in Mexican Quintana Roo

Relationship of PON1 activity and hsCRP concentration with disease status in patients with type 2 diabetes mellitus with and without retinopathy

Diabetes, impaired fasting glucose, daily life activities, food and beverage consumption among Buddhist monks in Chanthaburi Province, Thailand

One-hour postload plasma glucose levels is associated with the production of hydrogen peroxide in abdominal obese men with normal glucose tolerance

Antidiabetic and antioxidant effect of Swietenia macrophylla seeds in experimental type 2 diabetic rats

Berardinelli Seip congenital lipodystrophy presenting with neonatal diabetes mellitus due to a mutation in the AGPAT2 gene

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials